Ashish M. Sagrolikar
Net Worth

Last updated:

What is Ashish M. Sagrolikar net worth?

The estimated net worth of Mr. Ashish M. Sagrolikar is at least $4,400,879 as of 6 Sep 2025. He owns shares worth $157,759 as insider and has received compensation worth at least $4,243,120 in Zogenix, Inc. and Zogenix, Inc..

What is the salary of Ashish M. Sagrolikar?

Mr. Ashish M. Sagrolikar salary is $616,980 per year as Executive Vice President & Chief Operating Officer in Zogenix, Inc.. He also receives $541,240 as Executive Vice President & Chief Commercial Officer in Zogenix, Inc..

How old is Ashish M. Sagrolikar?

Mr. Ashish M. Sagrolikar is 58 years old, born in 1967.

What stocks does Ashish M. Sagrolikar currently own?

As insider, Mr. Ashish M. Sagrolikar owns shares in one company:

Company Title Shares Price per share Total value
Zogenix, Inc. (ZGNX) Executive Vice President & Chief Operating Officer 5,913 $26.68 $157,759

What does Zogenix, Inc. do?

Zogenix, Inc., a biopharmaceutical company, develops and commercializes therapies to transform the lives of patients and their families living with rare diseases in the United States. The company's lead product candidate is the Fintepla, a low-dose fenfluramine, which is in Phase III clinical trials for the treatment of seizures associated with Dravet syndrome, as well as to treat seizures associated with Lennox-Gastaut syndrome; and that is in Phase II clinical trials for the treatment of other rare epileptic syndromes and diseases. It is also developing MT1621, an investigational therapy for the treatment of a rare genetic disorder called thymidine kinase 2 deficiency. Zogenix, Inc. has a collaboration with Tevard Biosciences for the research, development and commercialization of novel gene therapies for Dravet Syndrome and other genetic epilepsies. The company was formerly known as SJ2 Therapeutics, Inc. and changed its name to Zogenix, Inc. in August 2006. Zogenix, Inc. was incorporated in 2006 and is headquartered in Emeryville, California.

ZGNX logo
ZGNX
Zogenix, Inc.
$26.68

Ashish M. Sagrolikar insider trading

Zogenix, Inc.

Transaction Date Security Shares Price per share Total value Source
Option
Restricted Stock Units 3,750 N/A N/A
Option
Common Stock 3,500 N/A N/A
Option
Restricted Stock Units 4,531 N/A N/A
Option
Common Stock 4,531 N/A N/A
Option
Common Stock 3,750 N/A N/A
Option
Restricted Stock Units 3,750 N/A N/A
Purchase
Common Stock 1,000 $25.45 $25,450
Option
Common Stock 2,032 N/A N/A
Option
Restricted Stock Units 2,032 N/A N/A
Option
Restricted Stock Units 3,750 N/A N/A
Option
Common Stock 3,750 N/A N/A

Zogenix key executives

Zogenix, Inc. executives and other stock owners filed with the SEC:

  • Dr. Bradley S. Galer (63) Executive Vice President & Chief Medical Officer
  • Dr. Gail M. Farfel (61) Executive Vice President & Chief Devel. Officer
  • Dr. Stephen J. Farr (66) Co-Founder, Chief Executive Officer, Pres & Director
  • Melinda Baker Senior Director of Corporation Communications
  • Mr. Ashish M. Sagrolikar (58) Executive Vice President & Chief Commercial Officer
  • Mr. Bret E. Megargel Vice President of Corporation Devel.
  • Mr. Jeff D. Durflinger Vice President of Technical Operations & Product Supply
  • Mr. Michael P. Smith (57) Executive Vice President, Chief Financial Officer, Treasurer & Sec.
  • Mr. Stephen H. Jenner Vice President of Marketing
  • Ms. Shawnte M. Mitchell Executive Vice President, Gen. Counsel & Sec.